Update: iSpecimen ISPC Bottom or Fake out?

ISPC

iSpecimen ISPC ran over 200% after our alert on November 22nd but as expected after an epic run like that, it will pull back. Since that 200% gain, ISPC has retraced to $5.39 just $.50 higher than what is was trading before the November explosion. It is official iSpecimen has fully retraced and could be ready for it’s next move up.

However, before you read this insightful information, sign up below, let’s stay in contact.

ISPC

iSpecimen ISPC announced last week, “the expansion of its supplier capabilities with the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants.” However, before we get started, let’s review some basic information on this company.

iSpecimen Company Summary

Company Name:  iSpecimen

Ticker: ISPC

Exchange: NASDAQ

Website: https://www.ispecimen.com/

ISPC Company Summary

iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. 

LVGI News

Jan. 13, 2022

Announced the expansion of its supplier capabilities with the addition of a reference lab in New York to support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants.

The reference lab, a recent addition to the iSpecimen supplier network, has the capacity to sequence hundreds of COVID-19 positive swabs per week, providing data that is crucial in the fight against the virus. This lab is sequencing the most recent swabs to identify new variants of COVID-19 as the virus continues to progress globally.

ISPC 1 Month Chart

ispc

iSpecimen 5 Day Chart

ISPC

ISPC Technical Analysis

ISPC needs to stay above $5.43 and new highs to be a bounce. If it doesn’t, it will be a head fake! It has consolidated and appears to be slightly bullish. This could be what we have been waiting for!

Remember, to never try and catch a falling safe, or a knife for that matter. Simply let it fall to the ground, walk over, and pick up the money and walk away. If you enjoyed this article, sign up below, I promise I will never spam you and I’m pretty darn good at picking winners. Let’s make some trades together!

ISPC

Reviva Pharma RVPH down big.

RVPH

Reviva Pharma RVPH down big on massive volume, to find out why take a look at this technical analysis by our Alexander Goldman down below

Reviva Pharmaceuticals RVPH Company Summary

Company Name:  Reviva Pharmaceuticals Holdings, Inc.

Ticker: RVPH

Exchange: NASDAQ

Website: https://ir.revivapharma.com/

Reviva Pharmaceutical Company Summary

Reviva Pharma RVPH is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families.

Also, Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208.

Therefore, Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and RP1208 in the United States (U.S.), Europe, and several other countries.

Why did RVPH go down?

Jan. 10th 2021

Reviva Pharma RVPH announced today the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with Phase 3 clinical investigation of its lead candidate, brilaroxazine, a novel serotonin and dopamine receptor modulator for the treatment of schizophrenia.

RVPH 3 Month Chart

PSTI

RVPH 1 Day Chart

PSTI

RVPH Technical Analysis

Reviva Pharmaceutical is looking bad, real bad. Don’t put it on your watchlist. It’s bearish all the way around.

Pluristem Therapeutics PSTI Collaboration

Pluristem Therapeutics PSTI

Pluristem Therapeutics PSTI signs a massive collaboration deal. Also, the stock looks great. Take a look below.

Pluristem Therapeutics PSTI Company Summary

Company Name:  Pluristem Therapeutics Inc.

Ticker: PSTI

Exchange: NASDAQ

Website: https://www.pluristem.com/  

Pluristem Therapeutics Company Summary

Pluristem is pushing the boundaries of science and engineering to create cell-based products for commercial use. The Company’s cell therapies advance the field of regenerative medicine, with potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation.

Moreover, pluristem Therapeutics’ sources its therapeutic cells from the placenta, an ethically accepted and potent source.

The Company’s manufacturing platform is a patented and validated state-of-the-art 3D cell expansion system. Pluristem’s method is uniquely accurate, cost-effective, and consistent from batch to batch.

Why did PSTI go up?

Jan. 10th 2021

Announced the launch of an innovative collaboration to develop, manufacture and commercialize cultured cell-based products for the food industry.

Therefore, the collaboration started with the incorporation of a new company (“NewCo”), that will receive exclusive, global, royalty bearing licensing rights to use Pluristem’s proprietary technology, intellectual property and knowhow, to be used in the field of cultured meat.

PSTI 3 Month Chart

Pluristem Therapeutics PSTI

PSTI 1 Day Chart

Pluristem Therapeutics PSTI

PSTI Technical Analysis

The $1.87 PPS for Pluristem Therapeutics PSTI is important before I would consider the trade. However, this stock is looking great! It gapped up big and pulled back for a minute and consolidated all day with a bullish lean.

Pluristem Therapeutics PSTI is possibly a winner, but I wouldn’t expect big things, probably sub 50% gains in the next few weeks.

Zynga ZNGA purchased for $12B

Zynga ZNGA purchased for $12B by Take-Two Interactive. ZNGA gaps up 46% with heavy trading volume this morning. Let’s take a closer look at Zynga.

Zynga Inc. ZNGA Company Summary

Company Name: Zynga Inc.

Ticker: ZNGA

Exchange: NASDAQ

Website: www.zynga.com 

[thrive_leads id=’9825′]

Zynga Inc. ZNGA Company Summary

Zynga ZNGA is a global leader in interactive entertainment with a mission to connect the world through games.

Therefore with it’s massive global reach in more than 175 countries and regions, Zynga has a diverse portfolio of popular game franchises that have been downloaded more than four billion times. Just on mobile including CSR Racing™, Empires & Puzzles™, FarmVille™, Golf Rival, Hair Challenge™, Harry Potter: Puzzles & Spells™, High Heels!, Dragons!™, Merge Magic!™, Toon Blast™, Toy Blast™, Words With Friends™ and Zynga Poker™.

With Chartboost, a leading mobile advertising and monetization platform, Zynga is an industry-leading next-generation platform with the ability to optimize programmatic advertising and yields at scale.

Founded in 2007, Zynga is headquartered in California with locations in North America, Europe and Asia.

Why did ZNGA go up over 40% overnight?

Jan. 10th 2021

Take-Two to acquire all the outstanding shares of Zynga for a total value of $9.861 per share – $3.50 in cash and $6.361 in shares of Take-Two common stock, implying an enterprise value of $12.7 billion.

Transaction represents a 64% premium to Zynga’s closing share price on January 7, 2022.

Establishes Take-Two as one of the largest publishers of mobile games, the fastest-growing segment of the interactive entertainment industry.

Unifies highly complementary businesses, including Take-Two’s best-in-class portfolio of console and PC games and Zynga’s industry-leading mobile franchises.

Creates one of the largest publicly traded interactive entertainment companies in the world, with $6.1 billion in trailing twelve-month pro-forma Net Bookings for the period ended September 30, 2021.

Consequently, Transaction expected to deliver approximately $100 million of annual cost synergies within the first two years after closing, and more than $500 million of annual Net Bookings opportunities over time.

Take-Two TTWO Company Summary

Company Name:  Take-Two Interactive Software, Inc.

Ticker: TTWO

Exchange: NASDAQ

Website: https://www.take2games.com/

Zynga Inc. ZNGA Company Summary

Headquartered in New York City, Take-Two Interactive Software, Inc. is a leading developer, publisher, and marketer of interactive entertainment for consumers around the globe.

We develop and publish products principally through Rockstar Games, 2K, Private Division, and T2 Mobile Games.

Take-Two TTWO products are designed for console systems, personal computers, and mobile, including smartphones and tablets.

Also, they deliver through physical retail, digital download, online platforms, and cloud streaming services. Take-Two TTWO common stock trades on NASDAQ under the symbol TTWO.

ZNGA 3 Month Chart

Zynga Inc. ZNGA

Zynga ZNGA 1 Day Chart

Zynga Inc. ZNGA

ZNGA Technical Analysis

After the announcement that Take-Two TTWO was acquiring Zynga Inc. ZNGA the stock gapped up with heavy trading volume by over 40%! Meanwhile TTWO suffers in PPS with a massive sell off.

ZNGA is shockingly consolidating after the massive run with a slight pullback. This is a good sign. Therefore, I would like to see it break $8.70 then $8.76 before I would take a position because normally there will be a massive sell off after a huge gap up like this.

[thrive_leads id=’9825′]

Petros Pharmaceuticals PTPI short squeeze

Petros Pharmaceuticals PTPI is possibly about to explode again as the short position increases as PPS is ticking up. Pay attention to PTPI as this stock may skyrocket

Petros PTPI company summary

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Exchange: NASDAQ

Short Squeeze Article: HERE

Petros PTPI Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why is it red HOT?

The NEWS:

Petros  reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. 

What did the say, “The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make 
The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

The Short Squeeze

Look HERE at our buddies over at Fintel.io. This stock has a big short position and could go crazy!

PTPI 5 Day Chart

PTPI 5 Day Analysis

The convergence point is coming Traders! All signs are pointing to a short squeeze! It is coming late Friday or Monday! Once PTPI breaks $2.82 & $2.90, boom like a rocket ship!

PTPI 1 Day Chart

1 Day Analysis

You can clearly see the $2.82 resistance. Get ready traders because I’ve been following PTPI for a while and I can hear the juice machine warming up for the BIG squeeze.

Breakout for Mainz Biomed MYNZ?

MYNZ - Breakout for Mainz Biomed

Mainz Biomed MYNZ develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. So, our traders have the ability to invest and feel good about helping the world while simultaneously investing!

The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.

The top 4 reasons Mainz Biomed B.V. (NASDAQ: MYNZ) is primed for a Massive breakout!

#1 MYNZ is Undervalued  

#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!

#3 Mainz Biomed Is Generating Revenue

#4 Philanthropic Investing feels good

Before we go over the top 4 reasons, let’s get acquainted with Mainz Biomed.

Company Name: Mainz BioMed

Ticker: MYNZ

Exchange: NASDAQ

Website: https://mainzbiomed.com/investors/

Mainz Biomed MYNZ Company Summary:

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.

ColoAlert is currently marketed across Europe with an FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval.

Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

[thrive_leads id=’9846′]

Why did it go up over 30% in just 21 trading days?

DECEMBER 7th, 2021

At-home Colorectal Cancer Diagnostic Test Now Available Online in Germany

Mainz Biomed announced the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test. German residents unable to obtain timely CRC screening via in-person physician visits, will be able to order ColoAlert directly to their home and receive highly accurate results within a maximum of nine working days. For more Info HERE

DECEMBER 14th, 2021

Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in Germany with their 5,500 labs.Mainz Biomed announced a partnership with leading diagnostics laboratory GANZIMMUN Diagnostics AG (GD), one of Europe’s leading laboratories for preventive and complementary medicine, for the commercialization in Germany of ColoAlert, Mainz’s unique, highly efficacious, and easy-to-use detection test for colorectal cancer. For More Info HERE

Now that we have a good understanding of why MYNZ is up 30%, let’s go over the top 4 reasons Mainz Biomed could be ready for a massive breakout!

#1 MYNZ is Undervalued  

#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!

#3 Mainz Biomed B.V.  Is Generating Revenue

#4 Philanthropic Investing feels good

#1 MYNZ is in a Multi-Billion Dollar Industry

Mainz Biomed has a Market Cap of $121 Million but when you look at other companies that are in the space, you can see the value in this diamond in the rough. I am very excited to see this kind of potential priced at such a low PPS and with a very small float at 12 Million shares outstanding.

Furthermore, Mainz plans on starting the FDA process shortly after their public listing.  Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to a market potential of over 52 million tests per year. 1  Can you imagine what will happen to the price per share of MYNZ when they get approved? Let’s look at one of their competitors to see what actually did happen!

Take a look at Mainz Biomed’s competitor Exact Sciences Corporation NASDAQ

Today, the top non-invasive colorectal screening test technology is manufactured by Exact Sciences (NASDAQ:EXAS), which is a perfect success story that Mainz BioMed is currently seeking to recreate. EXAS is valued at $17 BILLION and trades at $78 PPS! Could you imagine if MYNZ is trading at those PPS in the near future? That would be almost 700% gains, like turning $10,000 into $80,000. 

I do apologize, I tend to get excited about companies that are showing massive potential in a philanthropic industry. Invest and possibly make money while saving lives, it’s the cornerstone of the capitalism that Adam Smith promoted. Not this crony Capitalism!

Did you see the EXAS’ share price back in 08’ it fell to less than one dollar. Essentially, investors were basically saying Exact was worthless.But in June 2009, an announcement of a mutual collaboration and licensing agreement between Exact Sciences and the Mayo Clinic turned the company’s fortunes around.

However, it was in 2014 when the FDA approved Cologuard for use as a non-invasive colorectal cancer screening test, and the test’s inclusion in multiple national guidelines that truly made the stock take off.

Hmm… Isn’t Mainz seeking FDA approval! See the correlation? I do and you should too.

For investors of EXAS who got in as recently as mid-2016 have already seen their investment grow nearly 20x in just over 5 years. Today it’s worth nearly $17 billion USD.

20x Returns, that $10,000 would be $200,000

Here is the kicker, Mainz Biomed’s ColoAlert is designed to be easier to administer than Exact Sciences ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy. This is truly cutting edge medical testing at a fraction of the PPS of Exact Science.

MYNZ other competitor is Genescopy a privately help company making some moves

The reason I mention Geneoscopy is because this story is relevant, take a look at the investment level, $100M++!

Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health, announced November 17th the closing of a Series B financing, raising a total of $105 million through a combination of debt and equity.

The round is led by previous investors Lightchain Capital and NT Investments. Other investors in the round include Morningside Ventures, Labcorp, Cultivation Capital, BioGenerator Ventures, and Innovatus Capital Partners. HERE

That is an example of just how large this industry is and how much money is available to fund it. It’s cancer and it has affected almost everyone in one way or the other.

#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!

MYNZ 1 Month Chart Technical Analysis

As you can see the trend is very Bullish and has consolidated since the December 21st-December 28th run. The 30% run last month that started December 6th was very controlled and on moderate volume.

Next, let’s look at the 5 day chart to see what is happening lately.

MYNZ 5 Day Chart Technical Analysis

I’ve been waiting on this reversal and I was betting it would happen today and literally in the final hour of trading it happened. I love this chart! As you see from the month chart above a bullish move and then consolidation with a slight bearish lean. Consequently, I’ve been waiting for a confirmation of a reversal. As MYNZ reached $10.43 it confirmed the reversal and this may just take off like a rocket ship.

If you think the stock chart is good, wait until you see why. MYNZ is generating revenue and the street is watching.

#3 Mainz Biomed B.V.  Is Generating Revenue

ColoAlert has received CE accreditation and is approved for sale in Europe.1  European sales will provide near-term revenue potential, while they prepare for entry into the US market. Just last month, Mainz Biomed announced the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test.

This is significant, DTC (direct to consumer) test to see if you have cancer which will allow you to catch it early and have a 90% survival rate. However, only about 4 out of 10 colorectal cancers are found at this early stage. When cancer has spread outside the colon or rectum, survival rates are lower.

ColoAlert is designed for profitability, rapid commercial uptake, and broad consumer acceptance. The fact that Mainz Biomed is generating revenue in Europe and will be entering the US market with FDA approval is a massive sign for things to come. Make sure you keep MYNZ on your watchlist because the potential is substantial.

#4 Philanthropic Investing – possibly turn an amazing profit while helping people

It is rare for investors to be able to possibly have a home run  return on an investment while helping to alleviate senseless deaths with the 2nd most deadly form of cancer.Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%. However, only about 4 out of 10 colorectal cancers are found at this early stage. When cancer has spread outside the colon or rectum, survival rates are lower.

90% survival rate if detected early, guess what, ColoAlert detects early stage colon cancer. There is a solution and it is ready to come to market in the USA with FDA approval.

Why is Mainz Biomed your cake and icing for investors?

  1. ColoAlert Holds Potential as a Blockbuster Early Detection Test for Colorectal Cancer. Far less senseless deaths in regards to colon cancer!
  2. Mainz BioMed protects its intellectual property through trade secrets to control all critical reagents, processes and formulations. Protecting intellectual property is important for market capitalization! 
  3. Mainz Biomed MYNZ is developing proprietary genetic testing methods for pancreatic cancer. Once the distribution channel is developed, offering multiple products creates more than one revenue stream!
  4. Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity. Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy. 1

Let’s recap why Mainz Biomed MYNZ could be, THE massive breakout of 2022!

#1 MYNZ is Undervalued  

#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!

#3 Mainz Biomed B.V.  Is Generating Revenue

#4 Philanthropic Investing feels good

It is a rare opportunity in this world to have this kind of investment opportunity while also funding the act of saving lives. This is an easy fix, detect the 2nd most dangerous form of cancer early and you have a 90% survival rate. ColoAlert is the answer, we just need to stop what we are doing and place it on your watchlist, today!

 Happy Trading and remember, never try to catch a falling knife!

1 https://mainzbiomed.com/investors/

Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, MYNZ. Small Cap Exclusive has been hired by Awareness Consulting for a period beginning on January 4, 2021 to publicly disseminate information about (MYNZ) via website and email. We have been compensated $13,500 USD. We will update any changes to our compensation.

Read full disclaimer here.

Reliance Global Group RELI is very bullish

Let’s take a quick bird’s eye view of Reliance Global Group RELI and why RELI is up over 200% in less than two weeks. Before we get started, let’s go over the particulars.

Company Name: Reliance Global Group

Ticker: RELI

Exchange: NASDAQWebsite: https://www.relianceglobalgroup.com/

Reliance Global Group Company Summary:

Reliance Global Group, Inc. (NASDAQ: RELI, RELIW) is combining advanced technologies, with the personalized experience of a traditional insurance agency model.

Also, Reliance Global Group’s growth strategy includes both an organic expansion as well as acquiring well managed, undervalued and cash flow positive insurance agencies.

Why did it go up over 200%?

Reliance Global Group RELI announced a private placement of preferred stock, common stock and warrants for gross proceeds of $20.0 million before deducting the placement agent’s fees and other estimated offering expenses.

The offering is expected to close on or around December 27, 2021.

Reliance Global Group RELI 1 Day Chart:

RELI technical analysis

I expect it to consolidate in between $6.13 & $6.36 before the next move. I’m feeling good about this stock and believe with the big news and the overall bullish trend in the 5 day and 1 day that it is a stock to watch carefully! 

If the stock falls below $6.13, that is an indicator of a pullback so be careful!

(MBOT) Microbot Medical Analysis

(MBOT) Microbot Medical goes up 68%, what next?

Microbot Medical shares MBOT skyrocketed 67.3% with heavy volume toward a nine-month high on Monday. News was released that the pre-clinical medical device company announced an agreement with Stryker Corp SYK to develop the first dedicated robotic procedural kits for use in certain neurovascular procedures. 

Company Name: (MBOT) Microbot Medical

Ticker: (MBOT)

Exchange: NASDAQ

Website: http://www.microbotmedical.com

Company Summary:

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot’s current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Why did MBOT Microbot Medical go up?

Microbot Medical Inc. (Nasdaq: MBOT) announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company.

The company will collaborate with Stryker’s Neurovascular division to integrate its neurovascular instruments with Microbot’s LIBERTY Robotic System to develop the world’s first dedicated robotic procedural kits for use in certain neurovascular procedures

MBOT 1 Day Chart

MBOT Technical Analysis

(MBOT) pulled back from the open to a low of $7.38 from a high an open of $8.93 constituting a 21% retrace. So is the stock ready to bounce? It ran from the low of $7.38 to a high of $8.50 and the consolidated in that range.

Can it bounce? It will bounce like a basketball if it eclipses $8.50. If it doesn’t it will fail. I like it if it can cruise by $$8.50 in the morning!

Microbot is poised to be a big winner if it can break out of this consolidation pattern. Make sure to always trade with stop losses. Happy trading

Skip to content